Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex
Topics & Concepts
MedicineNivolumabRenal cell carcinomaIpilimumabNephrectomyAdjuvantPlaceboInternal medicineUrologyClinical trialCarcinomaOncologySurgeryGastroenterologyImmunotherapyKidneyCancerPathologyAlternative medicineRenal cell carcinoma treatmentFerroptosis and cancer prognosisBladder and Urothelial Cancer Treatments